Hear At Last Signs Exclusive Contract with Hebei Jiachen Integrated Housing Co. for Affordable Modular Homes in North and Central America as Well as the Caribbean
Miami, Florida--(Newsfile Corp. - October 21, 2025) - Hear At Last (OTCID: HRAL), a leader in innovative housing solutions, is pleased to announce an exclusive partnership with Hebei Jiachen Integrated Housing Co., a globally recognized manufacturer of high-quality modular homes. This new agreement grants Hear At Last the exclusive rights to represent and distribute Hebei Jiachen's affordable modular homes across North Central and America as well as the Caribbean. This str
Household / Consumer / Cosmetics, Health
2025-10-21 8:00 AM EDT | Hear AtLast Holdings, Inc
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-21 7:27 AM EDT | Cardiol Therapeutics Inc.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purcha
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-21 7:00 AM EDT | TempraMed Technologies Ltd
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the po
Healthcare and Hospitals, Health
2025-10-21 1:36 AM EDT | Cosmo Pharmaceuticals N.V.
Glow Lifetech Provides Commercial & Corporate Update; Launches New Key Accounts, Advances National Expansion
Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting new key account wins and expanding national distribution, building on its continued commercial growth. MOD™ Expands to 60+ One Plant Stores in Ontario & Saskatchewan Building on strong commercial momentum with key accounts in Ontario and the Company's recent
2025-10-20 4:15 PM EDT | Glow Lifetech Corp.
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an init
Technology, Pharmaceuticals, Health
2025-10-20 12:59 PM EDT | Republic Technologies Inc.
Republic Technologies Inc. kündigt geplante gesicherte Wandelanleihefazilität in Höhe von bis zu 100 Mio. USD an
Vancouver, British Columbia--(Newsfile Corp. - Montag, 20. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) ("das Unternehmen" oder "Republic") freut sich bekanntzugeben, dass es beabsichtigt, mit einem institutionellen Investor ("der Investor") eine Finanzierungsvereinbarung über eine geplante gesicherte Wandelanleihefazilität von bis zu 100 Mio. US-Dollar ("die geplante Wandelanleihefazilität") ("die geplante Finanzierung")
Technology, Pharmaceuticals, Health
2025-10-20 9:55 AM EDT | Republic Technologies Inc.
Republic Technologies Inc. Announces Up to US$100 Million Proposed Secured Convertible Note Facility Financing
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to announce that it proposes to enter into a financing agreement with an institutional investor (the "Investor") for a proposed secured convertible note facility of up to US$100 million (the "Proposed Convertible Facility") (the "Proposed Financing"), featuring an initial US
Technology, Pharmaceuticals, Health
2025-10-20 9:20 AM EDT | Republic Technologies Inc.
Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner
Burlington, Ontario--(Newsfile Corp. - October 20, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company developing innovative drug delivery solutions through its QuickStrip™ platform, today issued a comprehensive update on its nicotine strategy, including the extension of its exclusive pre-commercialization and development agreement (the "Agreement") with its international nicotine partner. The Agreement,
2025-10-20 8:48 AM EDT | Rapid Dose Therapeutics Corp.
Akanda Corp. Increasing Its Cannabis Investment
Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), through its cannabis operating subsidiary, has furthered its cannabis investment by extending its option on its British Columbia asset for two additional years. The Company has been working on obtaining its full cultivation license for a variety of potential products containing THC, but currently it is operating under its hemp cultivation license. A further extension of the license
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-10-20 8:00 AM EDT | Akanda Corp
Predictmedix AI Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announces a proposed non brokered private placement. The Company intends to issue (the "Offering") of up to 18,000,000 units (each, a "Unit") at a price of C$0.05 per Unit, for aggregate gross proceeds to the Company of up to C$900,000. Each Unit will be comprised of one c
2025-10-20 7:05 AM EDT | QScreen AI Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025 and October 10, 2025, it will be proceeding to complete its previou
Biotechnology, Pharmaceuticals, Health
2025-10-20 7:00 AM EDT | PreveCeutical Medical Inc.
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy ("THT"). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited int
2025-10-20 6:00 AM EDT | Sona Nanotech Inc.
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-17 4:34 PM EDT | Cardiol Therapeutics Inc.
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy treatment were recruited into this early feasibility stu
2025-10-17 4:04 PM EDT | Sona Nanotech Inc.
MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - October 16, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the sixth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The sixth tranche of the private placement consists of 263,428 Units of the Company (the "Units") at a price of $0.20 per Uni
Technology, Healthcare and Hospitals, Health
2025-10-16 6:00 PM EDT | MyndTec Inc.
Akanda To Accelerate Recurring Revenue with Expansion Of Up To 20 New Cellular Towers
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today a major network expansion initiative with the construction of new cellular towers within the proximity of its existing tower network. The Company plans to construct and/or acquire up to 20 new or existing towers/sites by the end of
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-10-16 4:15 PM EDT | Akanda Corp
El Salvador Emerges as a Prime Investment Destination with Historic Public Safety Gains and Bold Institutional Reforms
San Salvador, El Salvador--(Newsfile Corp. - October 16, 2025) - El Salvador is consolidating its position as a prime investment destination. In 2025, it recorded a remarkable surge in foreign direct investment (FDI) and offered a business environment strengthened by macroeconomic reform, regulatory efficiency, and historic advances in public safety. To build on this momentum, Invest in El Salvador, the country's promotional agency, will lead a U.S. roadshow this month, wi
Auto Manufacturers, Environmental Services, Energy, Health
2025-10-16 3:08 PM EDT | LinkUp Global